CR10049A - Derivados de tiadiazol como agentes antidiabéticos - Google Patents

Derivados de tiadiazol como agentes antidiabéticos

Info

Publication number: CR10049A
Authority: CR; Costa Rica
Prior art keywords: tiadiazol; derivatives; antidiabetic agents; antidiabetic; agents
Prior art date: 2005-12-08

Application number

CR10049A

Other languages

English (en)

Inventor

David Barnes

Gregory Raymond Bebernitz

Gary Mark Coppola

Katsumasa Nakajima

Travis Stams

Sydney Wolf Topiol

Thalaththani Ralalage Vedananda

James Richard Wareing

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-08

Filing date

2008-06-05

Publication date

2008-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10049(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-05 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-25 Publication of CR10049A publication Critical patent/CR10049A/es

Links

239000003472 antidiabetic agent Substances 0.000 title 1
229940125708 antidiabetic agent Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CR10049A 2005-12-08 2008-06-05 Derivados de tiadiazol como agentes antidiabéticos CR10049A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74857305P	2005-12-08	2005-12-08

Publications (1)

Publication Number	Publication Date
CR10049A true CR10049A (es)	2008-08-25

Family

ID=37950917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10049A CR10049A (es)	2005-12-08	2008-06-05	Derivados de tiadiazol como agentes antidiabéticos

Country Status (26)

Country	Link
US (1)	US7700633B2 (es)
EP (1)	EP1963292B1 (es)
JP (1)	JP2009519248A (es)
KR (1)	KR20080074969A (es)
CN (1)	CN101326173A (es)
AR (1)	AR056838A1 (es)
AT (1)	ATE546440T1 (es)
AU (1)	AU2006321905B2 (es)
BR (1)	BRPI0619600A2 (es)
CA (1)	CA2629857A1 (es)
CR (1)	CR10049A (es)
EC (1)	ECSP088506A (es)
ES (1)	ES2381280T3 (es)
IL (1)	IL191549A0 (es)
MA (1)	MA30202B1 (es)
NO (1)	NO20083031L (es)
NZ (1)	NZ568243A (es)
PE (2)	PE20100733A1 (es)
PL (1)	PL1963292T3 (es)
PT (1)	PT1963292E (es)
RU (1)	RU2008127254A (es)
TN (1)	TNSN08249A1 (es)
TW (1)	TW200732315A (es)
UA (1)	UA94724C2 (es)
WO (1)	WO2007067615A2 (es)
ZA (1)	ZA200804074B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA94921C2 (en) *	2005-12-08	2011-06-25	Новартис Аг	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
KR20080074966A (ko) *	2005-12-08	2008-08-13	노파르티스 아게	1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
CN101312957A (zh) *	2005-12-08	2008-11-26	诺瓦提斯公司	用于治疗由蛋白酪氨酸磷酸酶介导的疾病(ptpase)的1,2,5-噻唑烷衍生物
WO2008067527A1 (en) *	2006-12-01	2008-06-05	Novartis Ag	Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) *	2007-06-04	2009-09-16	Novartis Ag	Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5809157B2 (ja)	2010-10-08	2015-11-10	持田製薬株式会社	環状アミド誘導体
CA2834465A1 (en)	2011-04-28	2012-11-01	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
JP7579057B2 (ja) *	2016-12-23	2024-11-07	ザユニバーシティーオブクイーンズランド	血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤
CA3104507A1 (en) *	2018-06-21	2019-12-26	Calico Life Sciences Llc	Protein tyrosine phosphatase inhibitors and methods of use thereof
US12492180B2 (en)	2018-12-21	2025-12-09	Curia Spain, S.A.U.	Process and intermediates for the preparation of Voxelotor
MX2021010544A (es) *	2019-03-14	2021-10-01	Calico Life Sciences Llc	Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
US11691954B2 (en)	2019-10-18	2023-07-04	Betagenon Ab	Formulations
GB201915094D0 (en) *	2019-10-18	2019-12-04	Balticgruppen Bio Ab	New formulations
CA3163012A1 (en)	2019-12-12	2021-06-17	Yi Liu	Compositions and methods for potentiating immune activity
EP4077319A1 (en) *	2019-12-20	2022-10-26	Calico Life Sciences LLC	Protein tyrosine phosphatase degraders and methods of use thereof
CA3211545A1 (en) *	2021-03-11	2022-09-15	Liansheng Li	Heterocycles and uses thereof
CA3236854A1 (en) *	2021-11-11	2023-05-19	Andrew Bogdan	Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023150150A1 (en) *	2022-02-02	2023-08-10	Nerio Therapeutics, Inc.	Protein tyrosine phosphatase inhibitors and uses thereof
JP2025507292A (ja) *	2022-02-02	2025-03-18	ネリオセラピューティクス，インク．	プロテインチロシンホスファターゼ阻害剤およびその使用
US20250129032A1 (en) *	2022-02-02	2025-04-24	Nerio Therapeutics, Inc.	Protein tyrosine phosphatase inhibitors and uses thereof
CN119790052A (zh) *	2022-09-13	2025-04-08	金橘生物科技公司	苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) *	2022-09-30	2024-04-04	深圳众格生物科技有限公司	蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) *	2022-12-30	2024-07-04	Insilico Medicine Ip Limited	Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) *	2023-04-28	2024-10-29	中科中山药物创新研究院	噻二唑烷酮衍生物及其制备方法和应用
CN116496248B (zh) *	2023-05-06	2025-09-02	江苏艾科姆检测有限公司	一种溴氰虫酰胺杂质的合成方法
TW202500126A (zh)	2023-05-24	2025-01-01	美商金橘生物科技公司	雜環化合物及其用途
AU2024288616A1 (en) *	2023-07-11	2026-02-12	Shenzhen Zhongge Biological Technology Co., Ltd.	Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof
CN120004876B (zh) *	2023-11-16	2026-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) *	2023-12-04	2024-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025242216A1 (zh) *	2024-05-24	2025-11-27	杭州百新生物医药科技有限公司	吲哚啉类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ535545A (en) *	2002-04-03	2007-06-29	Novartis Ag	5-substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as PTPase 1B inhibitors
GB0225986D0 (en) *	2002-11-07	2002-12-11	Astrazeneca Ab	Chemical compounds
GB0227813D0 (en)	2002-11-29	2003-01-08	Astrazeneca Ab	Chemical compounds
AU2003300447B2 (en) *	2002-12-30	2009-09-03	Vertex Pharmaceuticals Incorporated	Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7141596B2 (en) *	2003-10-08	2006-11-28	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
KR20080074966A (ko)	2005-12-08	2008-08-13	노파르티스 아게	1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
CN101312957A (zh)	2005-12-08	2008-11-26	诺瓦提斯公司	用于治疗由蛋白酪氨酸磷酸酶介导的疾病(ptpase)的1,2,5-噻唑烷衍生物
WO2007115058A2 (en)	2006-03-31	2007-10-11	Novartis Ag	Thiadiazolidinone inhibitors of ptpase

2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 CA CA002629857A patent/CA2629857A1/en not_active Abandoned
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 EP EP06839094A patent/EP1963292B1/en active Active
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Ceased
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/en not_active Ceased
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2006321905B2 (en)	2011-08-11
ECSP088506A (es)	2008-07-30
AU2006321905A1 (en)	2007-06-14
WO2007067615A2 (en)	2007-06-14
US7700633B2 (en)	2010-04-20
PE20071031A1 (es)	2007-11-15
TW200732315A (en)	2007-09-01
WO2007067615A3 (en)	2007-11-15
EP1963292A2 (en)	2008-09-03
TNSN08249A1 (en)	2009-10-30
PT1963292E (pt)	2012-05-10
BRPI0619600A2 (pt)	2011-10-11
RU2008127254A (ru)	2010-01-20
EP1963292B1 (en)	2012-02-22
PL1963292T3 (pl)	2012-07-31
AR056838A1 (es)	2007-10-24
US20080262050A1 (en)	2008-10-23
JP2009519248A (ja)	2009-05-14
PE20100733A1 (es)	2010-10-29
ATE546440T1 (de)	2012-03-15
NZ568243A (en)	2011-07-29
ZA200804074B (en)	2009-03-25
UA94724C2 (en)	2011-06-10
ES2381280T3 (es)	2012-05-24
CN101326173A (zh)	2008-12-17
IL191549A0 (en)	2008-12-29
KR20080074969A (ko)	2008-08-13
CA2629857A1 (en)	2007-06-14
MA30202B1 (fr)	2009-02-02
NO20083031L (no)	2008-08-28

Legal Events

Date	Code	Title	Description
2014-05-06	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR10049A (es)	2008-08-25	Derivados de tiadiazol como agentes antidiabéticos
BRPI0508788A (pt)	2007-09-04	tiadiazolidinonas como inibidores de sqg - 3
BRPI0718266A2 (pt)	2014-01-07	Compostos heterocíclicos como agentes anti-inflamatórios.
BRPI0718494A2 (pt)	2014-01-21	Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
CR10039A (es)	2008-07-10	Derivados espirocíclicos
ATE510823T1 (de)	2011-06-15	Fungizide pyridinyloxysubstituierte phenylamidinderivate
DE602006021542D1 (de)	2011-06-09	Resolver-anordnung
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ITFI20050094A1 (it)	2006-11-07	Opercolatrice perfezionata
ATE485294T1 (de)	2010-11-15	Azaindol-2-carboxamid-derivate
EP1916896A4 (en)	2010-08-11	NOT STEROID-antiandrogens
ITRA20050029A1 (it)	2007-01-30	Macchina ginnica
ATE527255T1 (de)	2011-10-15	Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da)	2012-10-22	Tiglien-3-onderivater
DE602006007763D1 (de)	2009-08-27	Oberfräse
ITRA20050030A1 (it)	2007-02-04	Macchina ginnica
EP1867636A4 (en)	2010-06-02	PYRIDYLMETHYLSULFONDERIVAT
DE602006014973D1 (de)	2010-07-29	Neuartige cercosporamidderivate
EP1935879A4 (en)	2011-07-06	SUBSTITUTED CYCLOALKEN DERIVATIVE
DE502006006543D1 (de)	2010-05-12	Werkzeughalter
DE502006006589D1 (de)	2010-05-12	Teils
EP1946752A4 (en)	2009-07-22	ANTIALLERGIC MEDIUM
ATE541837T1 (de)	2012-02-15	Oxaphenanthren-derivate
PT1889059E (pt)	2009-10-01	Métodos de imunoensaio melhorados
DE602006011251D1 (de)	2010-02-04	Druckmaschinenanordnung